Pharmacogenetics, Enzyme Probes and Therapeutic drug Monitoring as Potential Tools for Individualizing Taxane Therapy

Abstract

The taxanes are a class of chemotherapeutic agents that are widely used in the treatment of various solid tumors. Although taxanes are highly effective in cancer treatment, their use is associated with serious complications attributable to large interindividual variability in pharmacokinetics and a narrow therapeutic window. Unpredictable toxicity occurrence necessitates close patient monitoring while on therapy and adverse effects frequently require decreasing, delaying or even discontinuing taxane treatment. Currently, taxane dosing is based primarily on body surface area, ignoring other factors that are known to dictate variability in pharmacokinetics or outcome. This article discusses three potential strategies for individualizing taxane treatment based on patient information that can be collected before or during care. The clinical implementation of pharmacogenetics, enzyme probes or therapeutic drug monitoring could enable clinicians to personalize taxane treatment to enhance efficacy and/or limit toxicity.

ABCB1 Variation Affects Myelosuppression, Progression‐free Survival and Overall Survival in Paclitaxel/Carboplatin‐treated Ovarian Cancer Patients

“…This currently limits the predictive value of ABCB1 genotyping before the start of paclitaxel treatment in clinical practice, based on our results. Our results are reflected in the contradictory results of previous studies , confirming that small variations in the composition of treatment regimens, and the selection of patient populations could influence the interpretation of the SNP effect on treatment outcome. Furthermore, the investigated variants might need different consideration depending on whether the aim is to minimize toxicity or maximize the antitumour effect of the treatment.…”

“…However, the results, from both our group and others, have yielded inconclusive and contradictory results , reviewed by Krens et al . and Fredericks et al . .…”

Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity

“…Consequently, clinical implementation of these findings would typically be to modulate the patient's dosage in order to achieve optimal drug exposure. 49 There are many examples of germline variants that may influence patient exposure to a cancer agent. 50 In this section, we highlight one of the more well-established examples, the influence of germline polymorphisms on exposure to irinotecan and its active metabolite, SN-38.…”

Inter-patient variability in docetaxel pharmacokinetics: A review

“…Compared with BSA-based dosing, using this method these researchers were able to reduce docetaxel's IIV significantly. However, the complexity of such methods, the interaction with several other mechanisms such as docetaxel transport and for example the interference with polysorbate 80, currently obstruct clinical application of these strategies [8,79,81,94].…”